Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 149 of 149 entries
Sorted by: Best Match Show Resources per page
Severe hypotension with loss of motor evoked potentials during cervical surgery prompting immediate cardiovascular resuscitation.

Surgical neurology international

Kim DC, Boyd EJ, Boyd TA, Granger HE, Menger RP.
PMID: 34221612
Surg Neurol Int. 2021 Jun 14;12:281. doi: 10.25259/SNI_336_2021. eCollection 2021.

BACKGROUND: Intraoperative neuromonitoring (IONM) is a well-established adjunct to spinal surgery to ensure safety of the neural elements.IONM has extremely high sensitivity and specificity for impending neurologic damage. In very rare instances, hypoperfusion of the cord may lead to...

Cite
Kim DC, Boyd EJ, Boyd TA, et al. Severe hypotension with loss of motor evoked potentials during cervical surgery prompting immediate cardiovascular resuscitation. Surg Neurol Int. 2021;12:281doi: 10.25259/SNI_336_2021.
Kim, D. C., Boyd, E. J., Boyd, T. A., Granger, H. E., & Menger, R. P. (2021). Severe hypotension with loss of motor evoked potentials during cervical surgery prompting immediate cardiovascular resuscitation. Surgical neurology international, 12281. https://doi.org/10.25259/SNI_336_2021
Kim, Daniel C, et al. "Severe hypotension with loss of motor evoked potentials during cervical surgery prompting immediate cardiovascular resuscitation." Surgical neurology international vol. 12 (2021): 281. doi: https://doi.org/10.25259/SNI_336_2021
Kim DC, Boyd EJ, Boyd TA, Granger HE, Menger RP. Severe hypotension with loss of motor evoked potentials during cervical surgery prompting immediate cardiovascular resuscitation. Surg Neurol Int. 2021 Jun 14;12:281. doi: 10.25259/SNI_336_2021. eCollection 2021. PMID: 34221612; PMCID: PMC8247696.
Copy Download .nbib Format: NLM
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Dermatology and therapy

Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.
PMID: 35025062
Dermatol Ther (Heidelb). 2022 Jan 13; doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13.

INTRODUCTION: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on...

Cite
Thaçi D, Strober B, Gordon KB, et al. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022;doi: 10.1007/s13555-021-00649-y.
Thaçi, D., Strober, B., Gordon, K. B., Foley, P., Gooderham, M., Morita, A., Papp, K. A., Puig, L., Menter, M. A., Colombo, M. J., Elbez, Y., Kisa, R. M., Ye, J., Napoli, A. A., Wei, L., Banerjee, S., Merola, J. F., & Gottlieb, A. B. (2022). Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and therapy, . https://doi.org/10.1007/s13555-021-00649-y
Thaçi, Diamant, et al. "Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial." Dermatology and therapy vol. (2022). doi: https://doi.org/10.1007/s13555-021-00649-y
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022 Jan 13; doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. PMID: 35025062.
Copy Download .nbib Format: NLM
Controlling the topology of mammalian mitochondrial DNA.

Open biology

Menger KE, Rodríguez-Luis A, Chapman J, Nicholls TJ.
PMID: 34547213
Open Biol. 2021 Sep;11(9):210168. doi: 10.1098/rsob.210168. Epub 2021 Sep 22.

The genome of mitochondria, called mtDNA, is a small circular DNA molecule present at thousands of copies per human cell. MtDNA is packaged into nucleoprotein complexes called nucleoids, and the density of mtDNA packaging affects mitochondrial gene expression. Genetic...

Cite
Menger KE, Rodríguez-Luis A, Chapman J, et al. Controlling the topology of mammalian mitochondrial DNA. Open Biol. 2021;11(9):210168doi: 10.1098/rsob.210168.
Menger, K. E., Rodríguez-Luis, A., Chapman, J., & Nicholls, T. J. (2021). Controlling the topology of mammalian mitochondrial DNA. Open biology, 11(9), 210168. https://doi.org/10.1098/rsob.210168
Menger, Katja E, et al. "Controlling the topology of mammalian mitochondrial DNA." Open biology vol. 11,9 (2021): 210168. doi: https://doi.org/10.1098/rsob.210168
Menger KE, Rodríguez-Luis A, Chapman J, Nicholls TJ. Controlling the topology of mammalian mitochondrial DNA. Open Biol. 2021 Sep;11(9):210168. doi: 10.1098/rsob.210168. Epub 2021 Sep 22. PMID: 34547213; PMCID: PMC8455175.
Copy Download .nbib Format: NLM
CCR5 is a potential therapeutic target for cancer.

Expert opinion on therapeutic targets

Hemmatazad H, Berger MD.
PMID: 33719836
Expert Opin Ther Targets. 2021 Apr;25(4):311-327. doi: 10.1080/14728222.2021.1902505. Epub 2021 Jun 14.

INTRODUCTION: Chemokines and their cognate receptors play a major role in modulating inflammatory responses. Depending on their ligand binding, chemokine receptors can stimulate both immune activating and inhibitory signaling pathways. The CC chemokine receptor 5 (CCR5) promotes immune responses...

Cite
Hemmatazad H, Berger MD. CCR5 is a potential therapeutic target for cancer. Expert Opin Ther Targets. 2021;25(4):311-327doi: 10.1080/14728222.2021.1902505.
Hemmatazad, H., & Berger, M. D. (2021). CCR5 is a potential therapeutic target for cancer. Expert opinion on therapeutic targets, 25(4), 311-327. https://doi.org/10.1080/14728222.2021.1902505
Hemmatazad, Hossein, and Berger, Martin D. "CCR5 is a potential therapeutic target for cancer." Expert opinion on therapeutic targets vol. 25,4 (2021): 311-327. doi: https://doi.org/10.1080/14728222.2021.1902505
Hemmatazad H, Berger MD. CCR5 is a potential therapeutic target for cancer. Expert Opin Ther Targets. 2021 Apr;25(4):311-327. doi: 10.1080/14728222.2021.1902505. Epub 2021 Jun 14. PMID: 33719836.
Copy Download .nbib Format: NLM
How to ensure the survival of the surgeon-scientist? The Homburg Program.

Menger MD, Schilling MK, Schafers HJ, Pohlemann T, Laschke MW.
UIID-AD: 2811
2012;397:619-22. doi: 10.1007/s00423-012-0925-9.

BACKGROUND: Academic surgery requires competence in research, teaching, and patient care. Because of the increasing complexity of both surgical research and clinical surgery, and additional skills necessary for adequate patient care, including economics, management, and organization, it becomes more...

Cite
Menger MD, Schilling MK, Schafers HJ, et al. How to ensure the survival of the surgeon-scientist? The Homburg Program. 2012;397:619-22doi: 10.1007/s00423-012-0925-9.
Menger, M. D., Schilling, M. K., Schafers, H. J., Pohlemann, T., & Laschke, M. W. (2012). How to ensure the survival of the surgeon-scientist? The Homburg Program. 397619-22. https://doi.org/10.1007/s00423-012-0925-9
Menger, M D, et al. "How to ensure the survival of the surgeon-scientist? The Homburg Program." vol. 397 (2012): 619-22. doi: https://doi.org/10.1007/s00423-012-0925-9
Menger MD, Schilling MK, Schafers HJ, Pohlemann T, Laschke MW. How to ensure the survival of the surgeon-scientist? The Homburg Program. 2012;397:619-22. doi: 10.1007/s00423-012-0925-9. UIID-AD: 2811.
Copy Download .nbib Format: NLM
Showing 145 to 149 of 149 entries